Alembic Pharmaceuticals Releases Q2 FY26 Results: Consolidated and Standalone Performance Details
Alembic Pharmaceuticals Limited announced the approval of its Consolidated and Standalone Unaudited Financial Results for the quarter ended June 30, 2026. The results, which were subjected to review by statutory auditors, detail the company's financial status across both levels of reporting as per data presented in their reports dated August 4, 2026.Consolidated Financial Performance (Quarter Ended 30 June 2026)
The consolidated results reflected key figures for the quarter ended 30 June 2026 compared against previous periods:| Particulars | Quarter Ended 30.06.2026 (Unaudited) | 31.03.2026 (Audited) | 30.06.2025 (Unaudited) | 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 2,149.77 Crores | 1,847.72 Crores | 1,710.72 Crores | 7,344.90 Crores |
| Total Income | 2,164.70 Crores | 1,873.22 Crores | 1,717.22 Crores | 7,399.31 Crores |
| Total Expenses | 1,943.23 Crores | 1,730.94 Crores | 1,526.67 Crores | 6,638.61 Crores |
| Profit Before Tax | 221.86 Crores | 143.38 Crores | 190.10 Crores | 760.94 Crores |
| Profit After Non-controlling interests | 173.07 Crores | 202.70 Crores | 154.38 Crores | 674.77 Crores |
| Total Comprehensive Income for the period | 174.63 Crores | 213.07 Crores | 154.33 Crores | 695.69 Crores |
Key Operational Notes (Consolidated):
Exceptional items for both the quarter and the year ended March 31, 2026 included a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility classified as held for sale under Ind AS 105, alongside employee benefit obligations arising from the revised definition of wages under the Labour Codes (Rs. 6.41 crore for the quarter and Rs. 48.64 crore for the year).
Standalone Financial Performance (Quarter Ended 30 June 2026)
The standalone results showed the following figures:| Particulars | Quarter Ended 30.06.2026 (Unaudited) | 31.03.2026 (Audited) | 30.06.2025 (Unaudited) | 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 1,868.06 Crores | 1,718.74 Crores | 1,494.17 Crores | 6,651.38 Crores |
| Total Income | 1,882.10 Crores | 1,744.62 Crores | 1,501.96 Crores | 6,197.28 Crores |
| Total Expenses | 1,626.19 Crores | 1,546.40 Crores | 1,376.44 Crores | 5,986.17 Crores |
| Profit Before Tax | 255.90 Crores | 198.21 Crores | 125.52 Crores | 721.10 Crores |
| Profit for the Period | 196.96 Crores | 243.07 Crores | 103.85 Crores | 640.42 Crores |
Financial Ratios and Health Metrics
The financial health indicators, covering both consolidated and standalone results, provided insights into the operational efficiency and debt levels of the company. Key metrics from the period ended 30 June 2026 included:Consolidated Ratio Summary (Rs in Crores):
| Metric | Value |
|---|---|
| Debt-Equity Ratio (times) | 0.28 |
| Net Worth (Rs. in Crores) | 5,856.21 |
| Current Ratio (times) | 1.69 |
| Long Term Debt to working capital (times) | 0.06 |
| Operating Margin (%) | 16.18% |
Standalone Ratio Summary (Rs in Crores):
| Metric | Value |
|---|---|
| Debt-Equity Ratio (times) | 0 |
| Net Worth (Rs. in Crores) | 5,819.40 |
| Current Ratio (times) | 1.75 |
| Operating Margin (%) | 19.26% |
Consolidated Business Overview
Alembic Pharmaceuticals Limited operates solely in the pharmaceuticals business and maintains one reportable segment. The results were reviewed by KKC & Associates, Chartered Accountants.Standalone Company Status
The company also provided an Independent Auditor's Review Report on the unaudited standalone financial results for the quarter ended 30 June 2026, confirming that the statement disclosed the required information and contained no material misstatement based on the review conducted in accordance with Ind AS 34.APLLTD Stock Price Movement
Alembic Pharmaceuticals Limited stock rallies in live trading, edging up to ₹823.15 as of 2:17 PM after gaining 2.16%. The equity sees strong interest today, with 73,831 shares transacted during the active market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.